Vantage logo

Oncology's haves and have-nots

A handful of tumour types have disproportionately benefited from the sector’s huge push into oncology. Is the investment case weakening in certain areas?

Vantage logo

Abbvergan by numbers

2019’s second mega-merger has emerged, and Vantage has crunched some EvaluatePharma data to help dissect the proposed deal.